After UnitedHealthcare's drug arm jacked up the price of inhalers, a young man with severe asthma had to go without — and then died.
Teva Pharmaceutical's Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. See why I ...
The parents of a 22-year-old Wisconsin man who died after an asthma attack have filed a lawsuit against Walgreens and ...
The parents of a young Wisconsin man have sued Walgreens and pharmacy benefit manager OptumRx over their son’s death from an ...
The family of a Wisconsin man is suing after they say he died from an asthma attack when his medication price rose from $66 ...
In Episode 4 of Shark Tank Season 10, entrepreneurs John and Chelsea Pinto found that sometimes the most refreshing ideas don't always lead to sweet deals.
The Humane Society of the United States argues the findings of a recent undercover investigation are grounds for banning the sale of puppies across Nevada.
The suit comes exactly one year after 22-year-old Cole Schmidtknecht died from cardiac arrest after suffering a severe asthma attack.
With the US capping inhaler prices at $35, competition between biologics and inhaled therapies is likely to intensify. However, biologics offering novel mechanisms of action, reduced dosing ...
A price hike is coming for folks with five or more lines on current plans and those still holding on to venerable plans no longer offered. David Lumb is a mobile reporter covering how on-the-go ...
will yield “maximum fair prices” that take effect in 2027. Also on the list are Xtandi, Ibrance, Calquence and Pomalyst, blockbuster drugs for cancers of the prostate, breast, blood and bone marrow.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback